BridgeBio Reports Positive Results from PROPEL 3 Study

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 3 days ago

0mins

BBIO-1.06%

Should l Buy BBIO?

Source: Newsfilter

Clinical Trial Success: The PROPEL 3 study successfully met its primary endpoint at Week 52, demonstrating a significant increase in annualized height velocity (AHV) with a mean treatment difference of +2.10 cm/year compared to placebo (p<0.0001), highlighting the drug's potential importance in pediatric growth.
Secondary Endpoint Breakthrough: In a pre-specified exploratory analysis, oral infigratinib achieved the first statistically significant improvement in body proportionality in children under 8 years old, showing an LS mean treatment difference of -0.05 against placebo (p<0.05), providing new clinical evidence for treatment.
Good Safety Profile: Oral infigratinib was well tolerated in the trial, with no discontinuations or serious adverse events related to the study drug, and only 3 cases (4%) of mild and transient hyperphosphatemia, indicating its potential for use in children.
Future Development Plans: BridgeBio plans to submit a New Drug Application (NDA) and Marketing Authorization Application (MAA) in the second half of 2026 and accelerate the development of infigratinib for hypochondroplasia, demonstrating the company's commitment to addressing unmet medical needs.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BBIO

Wall Street analysts forecast BBIO stock price to rise

17 Analyst Rating

17 Buy

0 Hold

0 Sell

Strong Buy

Current: 76.060

Low

69.00

Averages

87.63

High

100.00

Current: 76.060

Low

69.00

Averages

87.63

High

100.00

Oppenheimer

Trevor Allred

Outperform

maintain

$81 -> $83

2026-02-13

New

Reason

Oppenheimer

Trevor Allred

Price Target

$81 -> $83

AI Analysis

2026-02-13

New

maintain

Outperform

Reason

Oppenheimer analyst Trevor Allred raised the firm's price target on BridgeBio to $83 from $81 and keeps an Outperform rating on the shares. The firm says Phase 3 result demonstrated 1.74cm/year least-squares mean AGH improvement, which compares favorably to vosoritide/navepegritide results of 1.5-1.6cm/year, though perhaps incrementally disappoints vs. Propel 2 results. Hyperphosphatemia results may assuage concerns on safety, with only three subjects demonstrating mild, transient hyperphosphatemia, though concerns on long-term utilization may limit total commercial uptake, Oppenheimer adds. The firm considers the results in line with its thesis, and believes efficacy should support infigratinib as best-in-class drug with skewed uptake in the U.S. market vs. ex-U.S.

Bernstein

William Pickering

Outperform

maintain

$94 -> $100

2026-02-13

New

Reason

Bernstein

William Pickering

Price Target

$94 -> $100

2026-02-13

New

maintain

Outperform

Reason

Bernstein analyst William Pickering raised the firm's price target on BridgeBio to $100 from $94 and keeps an Outperform rating on the shares to reflect positive infigratinib data. The firm thinks there is much more of the skeletal dysplasia story still to play out, and the clean safety in particular gives Bernstein greater confidence in BridgeBio becoming the category leader. In terms of what's next for the stock, the firm believes there is still upside from positive revisions to both infigratinib and encaleret as focus shifts toward indication expansion in hypochondroplasia and chronic hypoparathyroidism, respectively.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBIO

Unlock Now

About BBIO

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

BridgeBio Pharma Stock Soars on Positive Clinical Trial Results

2 days agoBenzinga

Clinical Trial Results: BridgeBio Pharma's PROPEL 3 Phase 3 trial for oral infigratinib in children demonstrated a significant annualized height velocity increase, with an LS mean treatment difference of +1.74 cm/year compared to placebo, highlighting the drug's potential in treating achondroplasia.
Statistical Significance: In a pre-specified exploratory analysis of children under 8, infigratinib showed statistical significance against placebo with an LS mean decrease of -0.05, marking a significant breakthrough in randomized trials for achondroplasia treatment.
Regulatory Plans: BridgeBio intends to meet with regulatory authorities in the second half of 2026 to discuss plans for submitting a New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib, reflecting the company's confidence in future market opportunities.
Competitive Landscape: While BioMarin's Voxzogo is the first FDA-approved drug for achondroplasia, the positive results from BridgeBio's infigratinib clinical trials may shift the competitive dynamics and enhance the company's position in the rare disease market.

BRIDGEBIO STOCK RISES 10.44% FOLLOWING FAVORABLE LATE-STAGE TRIAL OUTCOMES FOR ORAL GENETIC DISORDER TREATMENT

3 days agomoomoo

Positive Trial Results: BridgeBio's drug for treating an oral genetic disorder has shown a 10.44% improvement in late-stage trial results.
Impact on Patients: The positive outcomes from the trial suggest potential benefits for patients suffering from this specific genetic condition.

BridgeBio Pharma Shares Surge 13% After Successful Phase 3 Trial of Infigratinib

3 days agoseekingalpha

Clinical Trial Success: BridgeBio Pharma reported success in its pivotal Phase 3 trial for infigratinib, with topline data indicating that the annualized height velocity (AAV) met the primary endpoint over 52 weeks, suggesting strong potential for market performance.
Key Secondary Endpoints Achieved: The global trial also met several key secondary endpoints, including changes in height Z-scores, indicating significant potential for the drug to improve patient height, thereby enhancing the company's competitive position in the rare disease market.
Good Safety Profile: No serious adverse events or trial discontinuations were reported, demonstrating the good tolerability of infigratinib, which may bolster regulatory confidence in the upcoming drug application submissions.
Future Development Plans: BridgeBio intends to meet with regulators in H2 2026 to discuss plans for New Drug Applications in the U.S. and EU, while also expediting the development of infigratinib for hypochondroplasia, reflecting the company's ongoing investment and strategic focus in this area.

BridgeBio Reports Positive Phase-3 Data for Infigratinib

3 days agostocktwits

Clinical Trial Results: BridgeBio Pharma's global PROPEL 3 trial, conducted over one year on children aged 3 to under 18, demonstrated that the experimental drug infigratinib significantly improved growth outcomes, achieving its primary study goal.
Height Velocity Increase: Children receiving infigratinib experienced an average annualized height velocity increase of over 2 centimeters compared to the placebo group, indicating the drug's effectiveness in promoting growth, which holds significant clinical implications.
Positive Market Reaction: Following the announcement of encouraging clinical trial results, BridgeBio Pharma's stock surged over 17% in Thursday's premarket trading, reflecting investor optimism regarding the drug's potential market value.
Future Development Potential: The study results not only lay the groundwork for further development of infigratinib but may also open new market opportunities for BridgeBio in the treatment of pediatric growth disorders, enhancing the company's competitive position.